Biomarker Discovery Solutions

In the immuno-oncology era, it’s becoming clear that understanding and improving response to cancer immunotherapies relies on the study of the interactions between tumor cells and immune cells in the Tumor Microenvironment (TME). Traditionally, gaining molecular insights into both the tumor and the immune system has required the analysis of data derived from multiple sources, packaged in various formats. When samples are both precious and limited, researchers need a way to both simplify this process and to maximize the data generated from each individual tumor sample. This is where ImmunoID NeXT™, built on the Personalis NeXT Platform®, is designed to address these challenges.